Progression of head and neck squamous cell cancer

Cancer and Metastasis Reviews

Volumn 24, Issue 1, 2005, Pages 107-127

  Tímár, József ^a   Csuka, Orsolya ^a   Remenár, Éva ^a   Répássy, Gábor ^b   Kásler, Miklós ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Head and neck cancer; Invasion marker; Lymphatic metastasis

Indexed keywords

ALPHA5 INTEGRIN; ALPHA6 INTEGRIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; COLLAGENASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; CYSTATIN C; FIBROBLAST GROWTH FACTOR 2; FOLLITROPIN; GENE PRODUCT; HERMES ANTIGEN; KI 67 ANTIGEN; LUTEINIZING HORMONE; MATRIX METALLOPROTEINASE; OSTEOPONTIN; PROTEIN C FOS; PROTEIN MDM2; PROTEIN P53; PROTEINASE; RAC1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F1; UVOMORULIN;

ANGIOGENESIS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL MIGRATION; DATA ANALYSIS; DRUG TARGETING; ENDOCRINE FUNCTION; GENE EXPRESSION PROFILING; GENETIC MARKER; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; LYMPH NODE METASTASIS; METASTASIS; METHYLATION; MOUTH CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TUMOR LOCALIZATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 17744380212     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-005-5051-5     Document Type: Review

References (113)

1. Stracke ML, Liotta LA: Multi-step cascade of tumor cell metastasis. In vivo 6: 309-316, 1992
2. O-charoenrat P, Pillai G, Patel S, Fisher C, Archer D, Eccles S, Rhys-Evans P: Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol 39: 386-390, 2003
3. Yuen APW, Lam KY, Lam LK, Ho CM, Wong A, Chow TL, Yuen WF, Wei WI: Prognostic factoras of clinically stage I and II oral tongue carcinoma - a comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features. Head Neck 24: 513-520, 2002
4. Narayana A, Vaughan TM, Kathuria S, Fisher SG, Walter SA, Reddy SP: p53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. Int J Radiation Oncology Biol Phys 46: 21-26, 2000
5. Gasco M, Crook T: The p53 network in head and neck cancer. Oral Oncol 39: 222-231, 2003
6. Sittel C, Ruiz S, Volling P, Kvasnicka HM, Jungehülsisng KM, Eckel HE: Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol 35: 583-589, 1999
7. de Vicente JC, Herreo-Zapatero A, Fresno MF, López-Arranz JS: Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: Clinicopathological and prognostic significance. Oral Oncol 38: 301-308, 2002
8. Lui M, Lawson G, Delos M, Jamart J, Ide C, Coche E, Weynand B, Desuter G, Hamoir M, Remacle M, Marbaix E: Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations. Head and Neck 25: 280-288, 2003
9. Naresh KN, Lakshminaraanan K, Pai SA, Borges AM: Apoptosis index is a predictor of metastatic phenotype in patients with early stage squamous carcinoma of the tongue. Cancer 91: 578-584, 2001
10. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M: S-phase kinase-associated protein 2 expression in laryngeal squamous cell carcinomas and its prognostic implications. Oncol Rep 10: 321-325, 2003
11. Lydiatt WM, Davidson PJ, Schantz SP, Carvana S, Chaganti RS: 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 20: 113-118, 1998
12. Vielba R, Bilbao J, Ispizua A, Zabalza I, Alfaro J, Rezola R, Moreno E, Elorriaga J, Alonso I, Baroja A, de la Hoz C: p53 Cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 113: 167-172, 2003
13. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, Tomita K, Komiyama S, Weinstein IB: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3355, 2002
14. Dong Y, Sui L, Sugmimoto K, Tai Y, Tokuda M: Cyclin D1-CDK4 complex, a possible critical factor for cell proliferation and prognosis in laryngeal squamous cell carcinomas. Int J Cancer (Pred Oncol): 95: 209-215, 2001
15. Tanaka N, Ogi K, Odajima T, Dehari H, Yamada S, Sonoda T, Kohama G: pRb2/p130 protein expression is correlated with clinicopathologic findings in patients with oral squamous cell carcinoma. Cancer 92: 2117-2125, 2001
16. Georgiou A, Gomatos IP, Ferekidis E, Syrigos K, Bistola V, Giotakis J, Adamopoulos G, Androulakis G: Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma. Eur J Surg Oncol 27: 574-580, 2001
17. Sidransky D: Molecular biology of head and neck tumors. In: DeVita T Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles & Practice of Oncology Lippincott-Raven Publishers, Philadelphia, 1997, p 735
18. Issa J-PJ: Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res 9: 2879-2881, 2003
19. Ogi K, Toyota, M, Ohe-Toyota, M, Tanaka N, Noguchi M, Sonoda T, Kohama G, Tokino T: Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8: 3164-3171, 2002
20. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JPJ: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686, 1999
21. Brock MV, Gou MG, Akiyama Y, Muller A, Wu TT, Montgomey E, Deasel M, Germonpre P, Rubinson E, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG: Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 9: 2912-2919, 2003
22. Remenár É, Számel I, Budai B, Gaudi I, Kásler M, Guny S: Serum sex steroid and hypophysis hormone levels of chronic alcoholics and head and neck cancer patients ad compared to normal controls. Hungarian Oncology 46: 329-332, 2002
23. Remenár É, Számel I, Budai B, Orosz Zs, Gaudi I, Kásler M, Gundy S: Hormonal influence in head and neck cancer. Hungarian Oncology 47: 155-159, 2003
24. Bhatavdekar JM, Patel DD, Vora HH, Shaj NG, Chikhlikar PR, Ghosh N: Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience. Head Neck 22: 257-264, 2000
25. Tavassoli M, Soltaninia J, Rudnicka J, Mashanyare D, Johnson N, Gaken J: Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced apoptosis: Role of TGF-betal. Carcinogenesis 23: 1569-1575, 2002
26. Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cel Biol 13: 167-171, 2001
27. Harris AL: Hypoxia - A key regulatory factor in tumour growth. Nature Rev Cancer 2: 38-47, 2001
28. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48: 149-156, 1998
29. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340, 2000
30. Ljungkvist AS, Bussink J, Rijken PF, Kaanders JH, van der Kogel AJ, Denekamp J: Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 54: 215-228, 2002
31. Wijffels KI, Kaanders JH, Rijken PF, Bussink J, van den Hoogen F, Marres HA, de Wilde PC, Raleigh JA, van der Kogel AJ: Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 83: 674-683, 2000
32. Dunst J, Stadler P, Becker A, Lautenschläger C, Poelz T, Hänsgen G, Molls M, Kuhnt T: Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onk 179: 521-526, 2003
33. Beasley NJP, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL: Hypoxia-inducible factors HIF-1α and HIF2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62:2493-2497, 2002
34. Shemiani B, Crowe DL: Hypoxic induction of HIF-1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 38: 251-257, 2002
35. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002
36. Murray JD, Carlson GW, McLaughlin K, Pennington M, Lynn M, DeRose PB, Williams JK, Cohen C: Tumor angiogenesis as a prognostic factor in laryngeal cancer. Am J Surg 174: 523-526, 1997
37. Beatrice F, Cammarota R, Giordano C, Corrado S, Ragona R, Sartoris A, Bussolino F, Valente G: Angiogenesis: prognostic significance in laryngeal cancer. Anticancer Res 18: 4737-4740, 1998
38. Gallo O, Masini E, Morbidelli E, Franchi A, Fini-Storchi I, Vergari WA, Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90: 587-596, 1998
39. Lopez-Graniel CM, Tamez de Leon D, Meneses-Garcia A, Gomez-Ruiz C, Frias-Mendivil M, Granados-Garcia M, Barrera-Franco JL: Tumor angiogenesis as a prognostic factor in oral cavity carcinoma. J Exp Clin Cancer Res 20: 463-468, 2001
40. Sion-Vardy N, Fliss DM, Prinsloo I, Shoham-Vardi I, Benharroch D: Neoangiogeneesis in squamous cell carcinoma of the larynx-biological and prognostic associations. Pathol Res Pract 197: 1-5, 2001
41. Tae K, El-Naggar AK, Yoo E, Feng L, Lee JJ, Hong WK, Hittelman WN, Shin DM: Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res 6: 2821-2828, 2000
42. Grammatica L, Piepoli S, D'Auria C, Achille G, Marzullo F, Zito FA, Labriola A, Salvatore C, Paradiso A: Primary tumours neoangiogenesis and P543 expression in oral carcinoma patients. J Exp Clin Cancer Res 20: 225-230, 2001
43. Lukits J, Tímár J, Juhász A, Döme B, Paku S, Répássy G: Progression difference between cancer of the larynx and hypopharynx is not due to tumor size and vascularization. Otolaryngol Head Neck Surg 125: 18-22, 2001
44. Pomerantz RG, Grandis JR: The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 5: 140-146, 2003
45. O-charoenrat P, Rhys-Evans PH, Eccles SA: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127: 813-820, 2001
46. Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW: Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer 93: 781-785, 2001
47. Smith BD, Smith GL, Carter D, DiGiovanna MP, Kasowitz KM, Sasaki CT, Haffty BG: Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 127: 780-785, 2001
48. Mineta H, Miura K, Ogino T, Takebayashi S, Misawa K, Ueda Y: Vascular endothelial growth factor (VEGF) expression correlates with p53 and Ki-67 expression in tongue squamous cell carcinoma. Anticancer Res 22: 1039-1044, 2002
49. Répássy G, Czigner J, Ribári O, Lapis K: The barrier-like role of activated connective tissue against the spread of supraglottic laryngeal carcinoma. Arch Otorhinolaryngol 245: 151-154, 1988
50. Chow V, Yue APW, Lam KY, Tsai GSW, Ho WK, Wei WI: A comparative study of clinicopathological significance of E-cadherin and catenins (αβ γ) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol 127: 59-63, 2001
51. Chang HW, Chow V, Lam KY, Wei WI, Yuen APW: Loss of E-cadherin expression resulting from promoter hypermethyalation in oral tongue carcinoma and its prognostic significance. Cancer 94: 386-392, 2002
52. Mercurio AM, Rabinovitz I, Shaw LM: The alpha 6 beta 4 integrin and epithelial cell migration. Curr Opin Cell Biol 13: 541-545, 2001
53. Ramos DM, But M, Regezi J, Schmidt BL, Atakilit A, Dang D, Ellis D, Jodan R, Li X: Expression of integrin β6 enhances invasive behavior in oral squamous cell carcinoma. Matrix Biol 21: 297-307, 2002
54. Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RCK: Tenascin and β6 integrin are overexpressed in floor of mount in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 38: 332-336, 2002
55. Li X, Yang Y, Hu Y, Dang D, Regezi J, Schmidt BL, Atakilit A, Chen B, Ellis D, Ramos DM: αvβ6-Fyn signaling promotes oral cancer progression. J Biol Chem 278: 41646-41653, 2003
56. Répássy G, Forste-Horváth Cs, Juhász A, Ádány R, Tamássy A, Tímár J: Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. Pathol Oncol Res 4: 14-21, 1998
57. Rodrigo JP, Dominguez F, Alvarez C, Gonzalez MV, Herrero A, Suarez C: Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous carcinoma of the supraglottic larynx. Am J Clin Pathol 118: 67-72, 2002
58. Kanke M, Fuji M, Kameyama K, Kanzaki J, Tokumaru Y, Imanishi Y, Tomita T, Matsumura Y: Clinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinoma. Jpn J Cancer Res 91: 410-415, 2000
59. Carinci F, Stabellini G, Calvitti M, Pelucchi S, Targa L, Farina A, Pezzetti F, Pastore A: CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg 13: 85-89, 2002
60. Maulu S-M, Luukkaa M, Grénman R, Jackson D, Jalkanen S, Ristamäki R: Intratumoral lymphatics are essential for the metastatic spread and prognosis is squamous cell carcinoma of the head and neck region. Cancer Res 63: 1920-1926, 2003
61. Lapis K, Tímár J: Role of elastin-matrix interactions in tumor progression. Semin Cancer Biol 12: 209-217, 2002
62. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A, Kubi T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6: 4635-4640, 2000
63. McCawley LJ, Matrisian LM: Matrix metallopoteinases: Multifunctional contributors to tumor progression. Mol Med Today 6: 149-156, 2000
64. Shimada T, Nakamura H, Yamashita K, Kawata R, Muakami Y, Fujimoto N, Sato H, Seiki M, Okada Y: Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: Implications for lymph node metastasis. Clin Exp Metast 18: 179-188, 2000
65. Yoshizaki T, Maruyama Y, Sato H, Furukawa M: Expression of tissue inhibitor of matrix metallopoteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J cancer (Pred Oncol) 95: 44-50, 2001
66. O-charoenat P, Rhys-Evans P, Eccles SA: Expression of vascular endothelial growth facto family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556-568, 2001
67. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95: 1902-1910, 2002
68. Budihna M, Strojan P, Smid L, Skrk, J, Vrhovec I, Zupevc A, Rudolf Z, Zargi M, Krasovec M, Svetic B, Kopitar-Jerala N, Kos J: Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem Hoppe Seyler 377: 385-390, 1996
69. Smid L, Strojan P, Budihna M, Skrk J, Vrhovec J, Zargi M, Kos J: Prognostic value of cathepsins B, L and stefins A and B in laryngeal carcinoma. Eur Arch Otolaryngol 254: 150-153, 1997
70. Strojan P, Budihna M, Smid L, Svetic B, Vrhovec I, Kos J, Skrk J: Prognostic significance of cysteine proteinases chathepsins B and L and their endogenous inhibitors stefins A and B patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 6: 1052-1062, 2000
71. Vlodavsky I, Goldsmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, Peretz T, Fridmann Y: Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 12: 121-129, 2002
72. Kurokawa H, Katsube K, Podyma KA, Ikuta M, Iseki H, Nakajima M, Akashi T, Omura K, Takagi M, Yanagishita M: Heparanase and tumor invasion patterns in human oral squamous cell carcinoma xenografts. Cancer Sci 94: 277-285, 2003
73. Ikuta M, Podyma KA, Maruama K, Enomoto S, Yanagishia M: Expression of heparanase in oral cancer cell lines and oral cancer tissues. Oral Oncol 37: 177-184, 2001
74. Tímár J, Csuka O, Orosz Zs, Jeney A, Kopper L: Molecular pathology of tumor metastasis. I. Predictive pathology. Pathol Oncol Res 7: 217-230, 2001
75. Silletti S, Paku S, Raz A: Tumor cell motility and metastasis. Autocrine motility factor and metastasis. Autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol Oncol Res 3: 230-254, 1997
76. Shimizu K, Tani M, Watanabe H, Nagamachi Y, Niinaka Y, Shiroishi T, Ohwada S, Raz A, Yokota J: The autocrine motility factor receptor gene encodes a novel type of seven tansmembrane protein. FEBS 456: 295-300, 1999
77. Nam SW, Clair T, Kim S, McMarlin A, Schiffmann E, Liotta LA, Stracke ML: Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61: 6938-6944, 2001
78. Niinaka Y, Haga A, Negishi A, Yoshimasu H, Raz A, Amagasa T: Regulation of cell motility via hign and low affinity autocrine motility factor (AMF) receptor in human oral squamous carcinoma cells. Oral Oncology 38: 49-55, 2002
79. Di Renzo MF, Olivero M, Matone T, Maffe A, Maggiora P, De Stefani A, Valente G, Giordano S, Cortesina G, Comoglio PM: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19: 1547-1555, 2000
80. Cotesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, Valente G, Comoglio PM, Di Renzo MF: Staging of head and neck squamous cell carcinoma using the met oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer (Pred Oncol) 89: 286-292, 2000
81. L in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer (Radiat Oncol Invest) 96: 41-54, 2001
82. Zeng Q, McCauley LK, Wang CY: Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. J Biol Chem 277: 50137-50142, 2002
83. Ranelletti FO, Almadori G, Rocca B, Ferrandina G, Ciabattoni G, Habib A, Galli J, Maggiano N, Gessi M, Lauriola F: Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer (Pred Oncol) 99: 343-349, 2001
84. Renkonen J, Wolff H, Paavonen T: Expression of cyclooxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 440: 594-597, 2002
85. Peng JP, Su CY, Chang HC, Chai CY, Hung WC: Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 33: 100-104, 2002
86. Lim S-C, Zhang S, Ishii G, Endoh Y, Kodama K, Miyamoto S, Hayashi R, Ebihara S, Cho J-S, Ochiai A: Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 10: 166-172, 2004
87. Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A: Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 299: 517-524, 2002
88. Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA, Tsue TT, Sanford TR: Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with had and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Sug 127: 1253-1259, 2001
89. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Masini E: Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis metastasis. Neoplasia 3: 53-61, 2001
90. Juhász A, Bádon H, Répássy G, Adány R: Characteristic distribution patterns of tenascin in laryngeal hypopharyngeal cancers. Laryngoscope 110: 84-92, 2000
91. Pepper MS, Skobe M: Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol 163: 209-213, 2003
92. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: Lymphangiogenesis and cancer metastasis. Nature Rev Cancer 2: 573-583, 2002
93. Nathanson SD: Insights into the mechanisms of lymph node metastasis. Cancer 98: 413-423, 2003
94. Van Trappen PO, Pepper MS: Lymphatic dissemination of tumour cells and the formation micrometastases. Lancet Oncol 3: 44-52, 2002
95. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Jackson DG, Skobe M: Molecular characterization of lymphatic endothelial cells. PNAS 99: 160069-16074, 2002
96. Jain RK, Fenton BT: Intratumoral lymphatic vessels: A case of mistaken identity or malfunction? J Natl Cancer Inst 94: 417-421, 2002
97. Irjala H, Alanen K, Grénman R, Heikkilä P, Joensuu H, Jalkanen S: Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res 63: 4671-4676, 2003
98. Genden EM, Ferlito A, Bradley PJ, Rinaldo A, Scully C: Neck disease and distant metastases. Oral Oncol 39: 207-212, 2003
99. Ferlito A, Shaha AR, Rinaldo A: The incidence of lymph node micrometastases in patients pathologically staged N0 in cancer of oral cavity and oropharynx. Oral Oncol 38: 3-5, 2002
100. Stoeckli SJ, Pfaltz M, Steinert H, Schmid S: Histopathological features of occult metastasis detected by sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma. Laryngoscope 112: 111-115, 2002
101. Chiesa F, Mauri S, Tradati N, Calabrese L, Giugliano G, Ansarin M, Andrle J, Zurrida S, Orecchia R, Scully C: Surfing prognostic factors in head and neck cancer at the Millennium. Oral Oncol 35: 590-596, 1999
102. Quon H, Liu FF, Cummings BJ: Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 23: 147-159, 2001
103. Le Q-T, Giaccia AJ: Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res 9: 4287-4295, 2003
104. Squire JA, Bayani J, Luk C, Unwin L, Tokunaga J, McMillan C, Irish J, Brown D, Gullane P, Kamel-Reid S: Molecular cytogenetic analysis of head and neck squamous cell carcinoma: By comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head Neck 24: 874-887, 2002
105. Hwang D, Alevizos I, Schmitt WA, Misra J, Ohyama H, Todd R, Mahadevappa M, Warrington JA, Stephanopoulos G, Wong DT, Stephanopoulos G: Genomic dissection for characterization of cancerous oral epithelium tissues using transcription profiling. Oral Oncology 39: 259-268, 2003
106. Leethanakul C, Knezevic V, Patel V, Amornphimoltham P, Gillespie J, Shillitoe EJ, Emko P, Park MH, Emmert-Buck MR, Strausberg RL, Krizman DB, Gutkind JS: Gene discovery in oral squamous cell carcinoma through the head and neck cancer genome anatomy project: confirmation by microarray analysis. Oral Oncol 39: 248-258, 2003
107. Dong G, Loukinova E, Chen Z, Gangi L, Chanturita TI, Liu ET, van Waes C: Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis and the NF-κB signal pathway. Cancer Res 61: 4797-4808, 2001
108. Chen Z, Zhang K, Zhang X, Yuan XH, Yuan Z, Jin L, Xiong M: Comparison of gene expression between metastatic derivatives and their poorly metastatic parental cells implicates crucial tumor-environment interaction in metastasis of head and neck squamous cell carcinoma. Clin Exp Metast 20: 335-342, 2003
109. Zhang X, Liu Y, Gilcrease MZ, Yuan XH, Clayman GL, Adler-Storthz K, Chen Z: A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer 95: 1663-1673, 2002
110. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shiongaki S, Kaji M, Saku T, Takagi R: Identification of potential biomarkers of lymph node metastasis is oral squamous cell carcinoma bay cDNA microarray analysis. Int J Cancer 106: 683-689, 2003
111. Harms JF, Welch DR, Miele ME: KISS1 metastasis suppression and emergent pathways. Clin Exp Metast 20: 11-18, 2003
112. Salerno M, Ouatas T, Palmieri D, Steeg PS: Inhibition of signal transduction by the NM23 metastasis suppressor: possible mechanisms. Clin Exp Metast 20: 3-10, 2003
113. Smiraglia DJ, Smith LT, Lang JC, Rush LJ, Dai Z, Schuller DE, Plass C: Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 40: 25-33, 2003